NLX-112

Neurolixis SAS · Phase 2 active Small molecule

At a glance

Generic name	NLX-112
Also known as	F13640, befiradol, 4-piperidinemethanamine, 1-(3-chloro-4-fluorobenzoyl)-4-fluoro-N-[(5-methyl-2-pyridinyl)-methyl], (2E)-2-butenedioate
Sponsor	Neurolixis SAS
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

[18F]-F13640 as a New Brain Radiopharmaceutical (EARLY_PHASE1)
Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia (PHASE2)
Exploration of Cluster Headache in a PET-MRI Study

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NLX-112 CI brief — competitive landscape report
NLX-112 updates RSS · CI watch RSS
Neurolixis SAS portfolio CI